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The viral enzyme integrase (IN) is essential for the replication of human immunodeficiency
virus type 1 (HIV-1) and represents an important target for the development of new
antiretroviral drugs. In this study, we focused on the N-terminal domain (NTD), which is
mainly involved into protein oligomerization process, for the development and synthesis
of a library of overlapping peptide sequences, with specific length and specific offset
covering the entire native protein sequence NTD IN 1–50. The most potent fragment,
VVAKEIVAH (peptide 18), which includes a His residue instead of the natural Ser at
position 39, inhibits the HIV-1 IN activity with an IC50 value of 4.5 µM. Amino acid
substitution analysis on this peptide revealed essential residues for activity and allowed
us to identify two nonapeptides (peptides 24 and 25), that show a potency of inhibition
similar to the one of peptide 18. Interestingly, peptide 18 does not interfere with the
dynamic interplay between IN subunits, while peptides 24 and 25 modulated these
interactions in different manners. In fact, peptide 24 inhibited the IN-IN dimerization,
while peptide 25 promoted IN multimerization, with IC50 values of 32 and 4.8 µM,
respectively. In addition, peptide 25 has shown to have selective anti-infective cell activity
for HIV-1. These results confirmed peptide 25 as a hit for further development of new
chemotherapeutic agents against HIV-1.
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INTRODUCTION
Integrase (IN) is a key enzyme for the integration of the HIV-1 genome into the host cell
chromosome and, therefore, a very promising target for anti-AIDS drug design. IN performs two
essential catalytic reactions. The first one takes place in the cytoplasm within particles termed
preintegration complex (PIC). IN cleaves the conserved dinucleotides GT from the 3′ ends
(3′-processing) of the double-stranded viral DNA, generating reactive 3′-hydroxyl DNA ends.
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Following translocation to the nucleus, IN uses the hydroxyl ends
as a substrate reaction for a nucleophilic attack integrating the
viral genome in the host chromosomal DNA (strand-transfer
reaction, STIN) (Semenova et al., 2006; Delelis et al., 2008).
IN is a protein of 32 kDa organized in three domains (Wang
et al., 2001; Chiu and Davies, 2004). The N-terminal domain
(NTD, residues 1–50) contains a zinc-binding H12H16C40C43
motif and contributes to protein oligomerization process
(Engelman and Craigie, 1992; Cai et al., 1997). The central
domain (CCD, residues 51–212) encloses the enzyme active site
characterized by the catalytic triad D64D116E152, which is highly
conserved in all INs, with the two residues D64 and D116 forming
a coordination complex with divalent ions like Mn2+ and Mg2+
(Goldgur et al., 1998; Chen et al., 2000). The C-terminal domain
(CTD, residues 213–288), which is the least conserved domain
between retroviral INs, binds non-specifically to DNA and is also
involved in IN multimerization (Chen et al., 2000).
Despite the CCD contains the catalytic site, in the absence
of the NTD and CTD domains, IN can only catalyze the
disintegration reaction in vitro, while it needs both the NTD
and CTD in a dimeric complex to catalyze 3′-processing and
strand-transfer reactions (Lia et al., 2011). Until now, only
inhibitors targeting the catalytic site of IN with a specific effect
on strand-transfer process (INSTIs) have been identified and
developed (Pommier et al., 2005; Savarino, 2006; Dayam et al.,
2008; Katlama and Murphy, 2012; Esposito and Tramontano,
2013). In 2007, the INSTI Raltegravir became the first IN
inhibitor approved for use in the treatment of HIV infected
patients (Evering and Markowitz, 2007; Summa et al., 2008).
More recently, the FDA also approved Stribild, a single-tablet
regimen HIV medication containing four drug combination of
Elvitegravir, another HIV INSTI, Cobicistat, a CYP3A inhibitor,
and Emtricitabine and Tenofovir DF, bothHIV nucleoside analog
reverse transcriptase inhibitors (Shimura et al., 2008; Brinson,
2013).
The emergence of the resistance to these drugs gives raise to
the pressing need of novel IN inhibitors (Mesplède et al., 2012).
However, absence of information on the structures of a full-
sized enzyme, on its complex with DNA and also on the PIC
composition and operation complicates and slows the search for
novel IN inhibitors.
To overcome these drawbacks, targeting allosteric sites of
the protein including interaction site of IN with cellular co-
factor essential for integration, for example the LEDGF/p75-IN
interaction, or oligomerization/multi oligomerization sites might
represent alternative approaches to IN inhibition (Zhao et al.,
2003; Li et al., 2006; Al-Mawsawi and Neamati, 2011; Maes et al.,
2012; Christ andDebyser, 2013; Long et al., 2013; Di Santo, 2014).
In this context, compounds that target the IN N-terminal
domain would be effective at disrupting IN function through
Abbreviations: IN, integrase; HIV-1, human immunodeficiency virus type 1; PIC,
preintegration complex; NTD, N-terminal domain; STIN, strand transfer integrase
reaction; CCD, catalytic core domain; CTD, C-terminal domain; INSTIs, integrase
strand transfer inhibitors (INSTIs); HOAt, 1-Hydroxy-7-azabenzotriazole; HOBt,
hydroxybenzotriazole; HBTU, N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-
yl)uraniumhexafluorophosphate; DIEA, N,N-diisopropylethylamine; DMF,
dimethylformamide.
a range of mechanisms, including allosteric or oligomerization
inhibition. We considered this domain an important starting
point for the identification of peptide inhibitors in order to clarify
some points on IN function in viral replication, such as the
elucidation of HIV-1 IN polymerization state, or its potentiality
in the structure-based design.
Here we present the design and synthesis of peptides
targeting the integration events by directly inhibiting IN or its
multimerization process. The synthesized peptides were assayed
in vitro for their ability to inhibit IN strand transfer activity
and for the capability to inhibit IN dimerization or to promote
IN multimerization. Finally, the most potent compounds,
conveniently conjugated with cell-penetrating fragment Tat, were
assayed inMT-4 cells for determining anti-HIV infective activity.
MATERIALS AND METHODS
Nα-Fmoc-protected amino acids, Rink amide-resin, HOAt,
HOBt, HBTU, DIEA, piperidine, and trifluoroacetic acid
were purchased from Iris Biotech (Germany). Rink Amide-
ChemMatrix resin was purchased from Biotage AB (Sweden).
Peptide synthesis solvents, reagents, as well as CH3CN for HPLC
were reagent grade and were acquired from commercial sources
and used without further purification unless otherwise noted.
Peptide Synthesis
The synthesis of IN analogs was performed according to the solid
phase approach using standard Fmoc methodology in a manual
reaction vessel and automated microwave synthesizer (Wang
et al., 1989; Malik et al., 2010). The first amino acid, Nα-Fmoc-
Xaa-OH (Nα-Fmoc-Asp(OtBu)-OH, Nα-Fmoc-Glu(OtBu)-OH,
Nα-Fmoc-His(N(im)trityl(Trt))-OH, Nα-Fmoc-Trp(Boc)-OH,
Nα-Fmoc-Ala-OH, Nα-Fmoc-Leu-OH, Nα-Fmoc-Val-OH,
Nα-Fmoc-Lys(Boc)-OH, Nα-Fmoc-Cys(Trt)-OH, Nα-Fmoc-
Met-OH, Nα-Fmoc-Ser(tBu)-OH, was linked on to the Rink resin
(100–200 mesh, 1% DVB, 0.59mmol/g) previously deprotected
by a 25% piperidine solution in DMF for 30min. The following
protected amino acids were then added stepwise. Each coupling
reaction was accomplished using a three-fold excess of amino
acid with HBTU (3 eq.) and HOBt (3 eq.) in the presence of
DIEA (6 eq.). The Nα-Fmoc protecting groups were removed
by treating the protected peptide resin with a 25% solution of
piperidine in DMF (1 × 5min and 1 × 25min). The peptide
resin was washed three times with DMF and the next coupling
step was initiated in a stepwise manner. The peptide resin was
washed with DCM (3×), DMF (3×), and DCM (3×), and the
deprotection protocol was repeated after each coupling step. In
addition, after each step of deprotection and after each coupling
step, Kaiser test was performed to confirm the complete removal
of the Fmoc protecting group, respectively, and to verify that
complete coupling has occurred on all the free amines on the
resin. The N-terminal Fmoc group was removed as described
above, and the peptides were acetylated adding a solution of
Ac2O/DCM (1:3) shaking for 30min. Finally the peptides were
released from the resin with TFA/iPr3SiH/H2O (90:5:5) for 3 h.
The resin was removed by filtration, and the crude peptide was
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recovered by precipitation with cold anhydrous ethyl ether to
give a white powder and then lyophilized.
Microwave Peptides Synthesis
The peptides Tat-18, Tat-24, and Tat-25 were synthesized using
a Biotage Syro Wave
TM
fully automated microwave and parallel
peptide synthesizer or assembled on the Automated Microwave
Peptide Synthesizer from Biotage AB (Initiator+ Alstra
TM
).
Peptides were synthesized on a Rink Amide-ChemMatrix
resin (150mg, loading 0.4–0.6mmol/g), previously deprotected
with 25% piperidine/DMF (1 × 3min, 1 × 10min) at room
temperature. The resin was then washed with DMF (4 × 4.5ml).
The following protected amino acids were then added on to the
resin stepwise. Coupling reactions were performed using Nα-
Fmoc amino acids (3.0 eq., 0.5M), using as coupling reagent
HBTU (3eq, 0.6M), HOAt (3eq, 0.5M), and DIEA (6eq, 2M)
in N-methyl-2-pyrrolidone (NMP). All couplings were achieved
for 10min at 75◦C (2×) and 2 × 45min at RT for histidine
and cysteine couplings to avoid the epimerization. After each
coupling step, the Fmoc protecting group was removed as
described above. The resin was washed with DMF (4 × 4.5ml)
after each coupling and deprotection step. Finally peptides were
released as described above.
Purification and Characterization
All crude peptides were purified by RP-HPLC on a preparative
C18-bonded silica column (Phenomenex Jupiter 100 proteo 90
Å, 100× 21.20mm, 10µm) using a Shimadzu SPD 10A UV−Vis
detector, with detection at 210 and 254 nm. The column was
perfused at a flow rate of 15 mL/min with solvent A (10%,
v/v, water in 0.1% aqueous TFA), and a linear gradient from
10 to 90% of solvent B (80%, v/v, acetonitrile in 0.1% aqueous
TFA) over 25min was adopted for peptide elution. Analytical
purity, retention time (tR) and peptides molecular weights were
determined by ESI mass spectrometry in Shimadzu a LC-MS
2010 instrument fitted with Phenomenex, Aeris XB-C18 column
(150mm× 4.60, 3.6µm).
IN Activity Inhibition Assay
Express Biotech International Company performed this assay
using its HIV-1 IN Assay kit (Xpressbio Life Science Products,
USA. www.xpressbio.com). Briefly, Streptavidin coated 96-well
plates were coated with a double-stranded HIV-1 LTR U5
donor substrate (DS) oligonucleotide containing an end-labeled
biotin. Full-length recombinant HIV-1 integrase protein was
then loaded onto this oligo substrate. Compounds were added to
the reaction and then a different double-stranded target substrate
(TS) oligo containing 3′-end modifications was added to the
plate. The sequence of DS DNA and TS DNA substrates used in
this assay were
5′-P ACC CTT TTA GTC AGT GTG GAA AAT CTC TAG
CAG T
GAA AAT CAG TCA CAC CTT TTA GAG ATC GTC A
and
5′ TGA CCA AGG GCT AAT TCA CT
ACT GGT TCC CGA TTA GAS GA
respectively (Hazuda et al., 1994 and Engelman et al., 1993).
The HIV-1 IN cleaves the terminal two bases from the exposed
3′-end of the HIV-1 LTR DS and then catalyzes a strand-transfer
reaction to integrate the DS into the TS. The products of the
reaction were detected colorimetrically using an HRP-labeled
antibody directed against the TS 3′-end modification. Percent
inhibition in the IN assay was calculated and IC50 values were
determined.
HTRF-Based IN Subunit Exchange Assay
Full-length IN and LEDGF proteins were expressed in E. coli
BL21(DE3) and were purified as described (Kessl et al., 2012;
Esposito et al., 2015; Tintori et al., 2015). His- and FLAG-tagged
INs, were mixed in 25 mM Tris (pH 7.4) buffer containing
150mM NaCl, 2 mM MgCl2, 0.1% Nonidet P-40, 1mg/ml BSA.
Test compounds were then added to the mixture. A mixture
of anti-His6-XL665 and anti-FLAG-EuCryptate antibodies were
then added to the reaction and, after an incubation, the plate
are read and the HTRF signal is calculated from the 665/620 nm
ratio.
Circular Dichroism (CD)
All CD spectra were recorded using a JASCO J710
spectropolarimeter at 20◦C between λ = 260–190 nm (1mm
path, 1 nm bandwidth, 4 accumulations, and 100 nm min−1
scanning speed). Measurements were performed with peptides
in H2O (0.100mM, pH 7.4) or in in 50% TFE/water solution.
Cell-Based Assays
The HIV-1 strain NL4.3 was obtained from the AIDS Research
and Reference Reagent Program (Division of AIDS, NIAID, NIH,
USA). The HIV-2 strain ROD was obtained from the Medical
Research Council (MRC, London, UK). The anti-HIV assay in
MT-4 cells has been described previously (Vermeire et al., 2004).
MT-4 cells (1× 106 cells/ml; 50µl of volume) were pre-incubated
for 30min at 37◦C with the test compounds in 96-well plates
(Falcon, BD Biosciences). The laboratory HIV strains (NL4.3 and
ROD) were added according to the 50% tissue culture infectious
dose (TCID50) of the viral stock. Cellular cytopathicity was
scored microscopically in MT-4 cells 5 days post-infection and
IC50s were calculated spectrophotometrically using MTS/PES.
For the latter viability assay, the Cell-Titer96 Aqueous One
Solution Proliferation Assay (Promega, Leiden, The Netherlands)
kit was used.
RESULTS
Design
Starting from HIV-1 IN NTD we synthesized an overlapping
peptide library to generate a library of peptide sequences of
specific length and specific offset, to cover the entire native
protein sequence NTD IN 1–50 (peptides 1–15, Figure 1). The
solution structure of NTD has been solved by 3D and 2D NMR
spectroscopy, classifying NTD as an “all alpha helix” structure. In
fact, it consists of three α helices, which range from residues 6–
15, 19–25, and 31–39, stabilized by a Zn2+ ion coordinated with
the HHCC motif (evidenced in Figure 1). Ile5, Ala8, Ile28, Ala33,
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FIGURE 1 | Sequences of the designed peptides in this study.
and Ile36 form part of the hydrophobic core, which explains their
importance for structural integrity (Eijkelenboom et al., 1997). As
showed in Figure 1, peptide 2 and peptides 6 and 7 include the
1rd α-helix and 2rd α-helix respectively, while peptide 11 forms
the 3rd α-helix of the NTD, and incorporates the Cys40 of the
HHCC motif.
The relevance of both a α-helix structure and a Zn2+ chelating
group on the inhibitory activity was assessed by the synthesis
of three peptides derived from peptide 11, in which the Cys
residue was deleted (peptide 16) or substituted by His amino
acid a residue also involved in the Zn2+ coordination (peptide
17) (Wolfe et al., 2001; Liao et al., 2013). The same His was also
used to replace the C-terminal Ser residue of peptide 16 leading
to peptide 18.
Biological Studies: HIV-1 IN Catalytic
Activity Inhibition
The synthetized peptides 1–18were tested in vitro for their ability
to inhibit the HIV-1 IN. Results showed that peptide 18 was the
most potent of the series and inhibit the HIV-1 IN activity with
an IC50 values of 4.5 µM (Table 1). Peptides 9 and 12 containing
the VVAK and VA fragments of peptide 18, respectively, and
peptide 2, which includes the 6–13 fragment of the first α-helix,
maintained a certain inhibitory activity. In this assay, we use
Raltegravir as a controls.
Base on the ability of inhibiting HIV-1 IN showed by peptide
18, we synthesized three peptides, in which Val at position
1, 2, and 7 was substituted with Phe (peptides 19, 20, and
21, respectively). In fact, Phe and Val differ in participating
helical assembly of the peptide molecules, and have different
hydrophobicity degree (Javadpour and Barkley, 1997; Azmi et al.,
2013). In addition, Phe could be involved in additional stacking
interactions with the viral target.
Subsequently, we established the contribution of the various
amino acid residues to the antiviral activity of peptide 18
TABLE 1 | Sequence, analytical data and effect of peptides 1–18 on HIV-1
IN activities.
Peptide Sequence HPLC ESI MS IN inhibition
k’ Found IC50(µM) ±SD
1 1FLDGIDKAQD 4.70 1163.1 NA
2 4GIDKAQDEHE 5.03 1182.5 162±9
3 7KAQDEHEKYH 4.63 1326.7 NE
4 10DEHEKYHSNW 4.75 1385.5 NA
5 13EKYHSNWRA 5.02 1363.7 NE
6 16HSNWRAMASD 2.94 1215.5 NE
7 19WRAMASDFNL 2.30 1251.7 NE
8 22MASDFNLPPV 1.30 1131.6 NA
9 25DFNLPPVVAK 3.70 1140.6 213 ± 12
10 28LPPVVAKEIV 4.40 1105.8 NA
11 31VVAKEIVASC 2.12 1059.7 NA
12 34KEIVASCDKC 3.06 1136.5 477 ± 23
13 37VASCDKCQLK 2.80 1135.5 NA
14 40CDKCQLKGEA 2.60 1135.4 NA
15 43CQLKGEAM 3.70 920.3 NA
16 31VVAKEIVAS 2.50 956.5 NA
17 VVAKEIVASH VVAKEIVAH 5.22 1094.0 NA
18 VVAKEIVAH 3.50 1007.0 4.5 ± 0.9
Raltegravir 0.18 ± 0.01
All peptide are acetylated and amidate at N terminal and C terminal respectively.
k’ [(peptide retention time – solvent retention time)/solvent retention time]. Peptide
concentration µM.
NE, No effect. The peptide demonstrated no significant effect in the IN assay, where the
percent activity for the compounds was found to be 100± 7% (As example see the dose-
response curve of peptide 5 in Supplementary Material).
NA, Not Applicable, 50% inhibition by the compound was not achieved (As example see
the dose-response curve of peptide 8 in Supplementary Material).
(peptides 22–28) through an L-Ala scanning analysis. The results
of the biological evaluation of these peptides are summarized in
Table 2.
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TABLE 2 | Sequence, analytical data, and effect of peptides 19–28 on
HIV-1 IN activities.
Peptide Sequence HPLC ESI-MS IN inhibition
k’ Found IC50(µM)
18 VVAKEIVAH 3.50 1007 4.5 ± 0.9
19 FVAKEIVAH 4.40 1054.4 NA
20 VFAKEIVAH 4.50 1054.5 375 ± 19
21 VVAKEIFAH 4.20 1054.2 504 ± 22
22 AVAKEIVAH 3.90 978.6 NA
23 VAAKEIVAH 4.20 978.4 NA
24 VVAAEIVAH 4.84 949.5 20.8 ± 1.3
25 VVAKAIVAH 4.05 948.6 13.0 ± 1.0
26 VVAKEAVAH 1.39 964.5 NA
27 VVAKEIAAH 3.90 978.5 NA
28 VVAKEIVAA 4.89 939.5 NA
Raltegravir 0.24 ± 0.02
All peptide are acetylated and amidate at C terminal and N terminal respectively.
k’ [(peptide retention time – solvent retention time)/solvent retention time]. Peptide
concentration µM.
NA = Not Applicable, 50% inhibition by the compound was not achieved (as example see
the dose-response curve of peptide 19 in Supplementary Material).
Replacement of the Val residue for the bulky-aromatic Phe
led to a strong reduction of the activity of the corresponding
peptides 19–21 compared with 18, indicating the importance of
this ramified amino acid on the HIV-1 IN inhibition capability.
This result was also confirmed with the data from the Alanine
scanning study. In fact, the substitution of Val1 or Val2 or
Val7 residues by Ala produced a dramatic loss of the HIV-
1 IN inhibitory activity of the corresponding analogs (22, 23,
and 27). The most interesting result was obtained with peptides
24 and 25. In these cases, the substitution by Ala of Lys4 or
Glu5, respectively, produced only a weak decrease of HIV-1 IN
inhibitor ability if compared to the hit peptide, suggesting that a
lack of polar side chains in these positions or the introduction of
low hindrance, lipophilic features is well accepted.
Conformational Studies
Circular Dichroism was used to determine the conformational-
activity relationships of peptide 18 and its analogs (22–28).
Analysis of spectra acquired in water solution indicated that
all peptides are random coil in water (data not shown). In
contrast, spectra acquired in 50% TFE/water solution (TFE,
trifluoroethanol) indicate that peptides have high tendency to
fold as α helix in fluoroalcohol solution (Figure 2). In particular,
all peptides have similar high helical content (about 40%) except
peptide 25 whose helical content is lower (about 10%).
IN-IN Dimerization and IN Multimerization
Studies
Taking in consideration that these peptides represent fragments
of NTD domain, which is involved in different and essential
process of the IN activity (Engelman and Craigie, 1992; Cai
et al., 1997), we wondered whether they were able to inhibit
the IN-IN dimerization or stabilizing the IN in the multimeric
FIGURE 2 | CD Spectra of selected peptides in TFE/water 50%
solution. Peptide are represented in: 18 (solid blue line), 22 (solid red line), 23
(solid black line), 24 (solid purple line), 25 (dashed black line), 26 (solid orange
line), 27 (dashed blue line), 28 (dashed red line).
form. In fact, it has been reported that allosteric compounds
inhibit IN activity binding a site that is different from CCD
binding site and working as disruptors of the IN dimer formation
(Christ and Debyser, 2013). To verify whether active peptides
18, 24, and 25 can modulate the dynamic interplay between
IN subunits, we tested them using an HTRF-based IN subunit
exchange assay. In this assay two IN preparation are used:
a first His-tagged IN preparation, and a second Flag-tagged
IN preparation. In both preparations the purified IN is at
equilibrium as a dimer; such dimers go through monomers
exchange. Hence, in the assay the monomer exchange of the two
different preparations leads to the formation of a dimer with one
His-tagged subunit and one Flag-tagged subunit. The formation
of this “hybrid” dimer can be monitored in the HTRF-based
assay as described (Esposito et al., 2015; Tintori et al., 2015).
When the assay is performed in the presence of a compound
inhibiting dimerization, the HTRF signal decreases as the
concentration of compound increases, whereas in the presence
of a compound promoting IN multimerization (association of
dimers) the HTRF signal increases as the concentration of
the compound increases. We found that peptides 24 and 25
modulate the interactions between the IN subunits in different
manners using the allosteric inhibitor LEDGIN-6 as a control
(Table 3). In fact, peptide 24 was able to inhibit the IN-
IN dimer formation with an IC50 value of 32 µM, but did
not affect IN multimerization, while peptide 25 promoted IN
multimerization, with a concentration of compound stimulating
the Multimerization Increase by 50% (MI50 value) of 4.8 µM,
but did not inhibited IN multimerization. While the reason
for this different behavior was not clear, it demonstrates that
IN multimerization can be differently modulated by interfering
with the NTD sequence. Differently, peptide 18 was not able
to modulate the dimer/multimer formation. Hence, the three
peptides showed three different modes of IN inhibition in
biochemical assays.
Cell-Based HIV Replication Assay
Themost potent peptides 18, 24, and 25, conveniently conjugated
with the cell-penetrating fragment Tat, were evaluated for
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TABLE 3 | Effects of peptides 18, 24, and 25 on the HIV-1 IN dimerization
and multimerization process.
Compounds Sequence IN-IN subunit exchange IN-multim
aIC50(µM)
cMI50(µM)
18 31VVAKEIVAH >100 (100%)b >100 (100%)
24 VVAAEIVAH 32 ± 3 >100 (100%)
25 VVAKAIVAH >100 (100%) 4.8 ± 0.4
LEDGIN-6 >100 (100%) 10 ± 1
a Compound concentration required to inhibit the HIV-1 IN-IN subunit exchange by 50%.
b Percentage of control measured in the presence of 100 µM concentration.
c Compound concentration required to inhibit the multimerization increase by 50%.
TABLE 4 | Evaluation of the synthesized peptides against HIV-1 and HIV-2
replication in MT-4 cell cultures.
Peptides ECa
50
(µM) CCb
50
(µM)
HIV-1 (NL4.3) HIV-2 (ROD) MT-4
Tat-18 >105 >105 105
Tat-24 >50 >50 >50
Tat-25 4.0 ± 0.6 >21.4 21.4 ± 2.0
a 50% Effective concentration, or compound concentration required to inhibit HIV-induced
cytopathogenic effect in MT-4 cell culture.
b Compound concentration required to reduce by 50% MT-4 cell viability.
their capability to inhibit the HIV-1 replication in CD4+
MT-4 cells (Table 4). The conjugated peptides 18 and 24
were devoid of antiviral activity when evaluated against HIV
replication. In contrast, 25 showed marked inhibitory potency
with good selectivity against HIV-1 (IC50 value in the low
micromolar range, accordingly with the results on IN catalysis
and dimerization, and selective index of 5.4), but not against
HIV-2.
DISCUSSION
A library of peptides was developed from the NTD sequence (1–
50) by using a mimotopic strategy. Preliminary results of the
in vitro integrase assay indicated that the fragment VVAKEIVAH
(peptide 18), which includes a His residue instead of the natural
Ser at position 39, reduced significantly the HIV-1 IN activity
showing an IC50 value of 4.5 µM. Peptide 18 is included into the
sequence of the 3rd α-helix of the NTD, which is located on the
dimerization interface within the context of the crystal structure
of this domain (Cai et al., 1997). Accordingly, we observed
significant changes in potency of this peptide when lipophilic and
ramified residues involved in the interaction between subunits,
such as Val1, Val2, Ile6, and Val7 are substituted. Ala scanning
showed also that loss of a lysine positively charge or a glutamate
negatively charge does not modify substantially the inhibitory
activity of the resulting peptides (24 and 25, respectively).
According to the circular dichroism results, the inhibitory
activity of these compounds does not seem to be related to
their ability to form helical structures. In fact, inactive peptides
22, 23, 26, 27, and 28 all show similar helical content as 18
and 24. On the other hand, compound 25 shows a significant
reduction of helical tendency but is approximately as active as
18. Recently, an approach to develop new HIV-1 IN inhibitors
that bind in a pocket different from the active binding site,
lead to the discovery of new drugs that are able to interfere
with the IN dynamic interplay, in two possible ways (Kessl
et al., 2012). In the first one, the molecules interfere with the
IN dimer-dimer formation, while the second, the molecules
promote the IN multimerization. In this case, IN is trapped in
a multimeric form in which the movements of the individual
subunits are restricted, and, as a consequence, also the catalytic
process. We tested peptides 18, 24, and 25 on HTRF assays to
determine their potential mechanism of actions and to verify
whether they were capable to inhibit the HIV-1 IN. Peptide 24
was able to inhibit the IN-IN dimer formation, while peptide
25 stabilizes the multimeric form of IN. Differently, peptide
18 was not able to modulate the dimer/multimer formation.
These data suggest that the modulation of IN dimerization
and/or multimerization process could be determined by the
net charge of the synthetized peptides, or more specifically
by their ability to form intermolecular salt bridges between
Glu5 (peptide 24) or Lys4 (peptide 25) residues and Lys or
Asp/Glu residues of different subunits, respectively (Michel
et al., 2009; Lia et al., 2011). This hypothesis, however, is
less probable for peptide 18, in which the formation of an
intramolecular salt bridge between adjacent residues Lys4 and
Glu5 prevents their interactions with acid and basic residues of
other subunits. In this case, the in vitro inhibitory activity of
peptide 18 could be related to its ability of inhibiting IN-DNA
interactions.
Interestingly, peptide 25, conjugated with the cell-penetrating
Tat fragment, is the only compound into this series able to
inhibit the HIV-1-induced cytopathogenic effect in MT-4 cell.
Our results indicate that the presence of a negative charge (Glu5
side chain) is detrimental for the inhibition of HIV replication
in target CD4 T cells (analogs 18 and 24), while the positively
charged Lys4 residue (peptide 25) plays an important role in
the potential antiviral activity. In addition, this peptide has
shown to have potent and selective antiviral activity for HIV-
1. Although the antiviral activity is about five-fold lower than
the concentration of its cellular toxicity, peptide 25 represents a
suitable lead compound for the development of novel derivatives
with improved toxicity profile.
Overall, our data confirm the hypothesis that peptides derived
from the protein of interest may be used to identify domains
which are important for catalytic activity, protein−protein
interactions, and/or multimerization process (Li et al., 2006;
Lia et al., 2011). Data in Tables 1–3 reflect also the difficulties
in identifying inhibitor compounds whose biological target is
the viral integration process (Liao et al., 2010). In fact, the
modification or replacement of a single amino acid in the
sequence of the most potent compound in this series (peptide
25), determines the diminution or loss of the target activity.
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The identification of the amino acid residues implicated in the
inhibition of IN activity highlights the importance of studies that
identify such residues and investigates possible roles for them (Li
et al., 2006).
In conclusion, this study shows that the modified 31–
39 sequence of the N-terminal domain of HIV integrase
(VVAKAIVAH, peptide 25) is able to interfere with functional
integration of the HIV-1 enzyme. This peptide conveniently
conjugated (peptide tat-25) inhibits the HIV activity in cell
culture probably due to its ability to stabilize the IN multimeric
form. Our peptide, one of the few in cell active peptides reported
to date, could be considered as a suitable hit compound in the
development of novel anti-HIV1 peptidomimetic agents with
a mechanism of action different to that the approved anti-IN
drugs.
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